Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Ugurel-Becker Selma |

** = Publikationen gelistet in SCI/SSCI/Pubmed

2018

Originalarbeiten (Zeitschrift)

** Fan, K; Ritter, C; Nghiem, P; Blom, A; Verhaegen, ME; Dlugosz, A; Dum, N; Woetmann, A; Tothill, RW; Hicks, RJ; Sand, M; Schrama, D; Schadendorf, D; Ugurel, S; Becker, JC Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma
CLIN CANCER RES. 2018; 24(23): 5873-5882. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2017

Originalarbeiten (Zeitschrift)

** Ofner, R; Ritter, C; Heidenreich, B; Kumar, R; Ugurel, S; Schrama, D; Becker, JC Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients.
J Cancer Res Clin Oncol. 2017; 143(4):613-617 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Ofner, R; Ritter, C; Ugurel, S; Cerroni, L; Stiller, M; Bogenrieder, T; Solca, F; Schrama, D; Becker, JC Non-reproducible sequence artifacts in FFPE tissue: an experience report.
J Cancer Res Clin Oncol. 2017; 143(7):1199-1207 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Ritter, C; Fan, K; Paschen, A; Reker Hardrup, S; Ferrone, S; Nghiem, P; Ugurel, S; Schrama, D; Becker, JC Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma.
Sci Rep. 2017; 7(1):2290-2290 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2016

Originalarbeiten (Zeitschrift)

** Willmes, C; Kumar, R; Becker, JC; Fried, I; Rachakonda, PS; Poppe, LM; Hesbacher, S; Schadendorf, D; Sucker, A; Schrama, D; Ugurel, S SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma.
Oncotarget. 2016; 7(9): 10117-10132. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Kurzbericht/Letter

** Lee, SB; Weide, B; Ugurel, S; Mossner, R; Enk, A; Hassel, JC Vemurafenib-induced granuloma annulare
J DTSCH DERMATOL GES. 2016; 14(3): 305-308.
Web of Science PubMed FullText FullText_MUG

 

2015

Originalarbeiten (Zeitschrift)

** Køllgaard, T; Ugurel-Becker, S; Idorn, M; Andersen, MH; Becker, JC; Straten, PT Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes.
PLoS One. 2015; 10(7):e0131934-e0131934 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Übersichtsarbeiten

** Mössner, R; Zimmer, L; Berking, C; Hoeller, C; Loquai, C; Richtig, E; Kähler, KC; Hassel, JC; Gutzmer, R; Ugurel, S Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature.
J Eur Acad Dermatol Venereol. 2015; 29(9):1797-1806 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Abstracts (Zeitschrift)

** Ugurel, S; Loquai, C; Terheyden, P; Schadendorf, D; Richtig, E; Utikal, J; Gutzmer, R; Rass, K; Sunderkotter, C; Stein, A; Fluck, M; Kaatz, M; Trefzer, U; Hauschild, A; Stadler, R; Berking, C; Pehamberger, H; Kopp-Schneider, A; Becker, JC Ex-vivo sensitivity-directed combination chemotherapy compared to DTIC monochemotherapy in chemo-naive advanced metastastic melanoma (ChemoSensMM): a multicenter randomized phase-3 DeCOG trial
J DTSCH DERMATOL GES. 2015; 13: 18-19.-25. Deutscher Hautkrebskongress; Sept 10-12, 2015; München. [Oral Communication]
Web of Science

 

2014

Originalarbeiten (Zeitschrift)

** Buder, K; Müller, PA; Beckmann, G; Ugurel, S; Bröcker, EB; Becker, JC Denileukin diftitox plus total skin electron beam radiation in patients with treatment-refractory cutaneous T-cell Lymphoma (mycosis fungoides): report of four cases.
Acta Derm Venereol. 2014; 94(1):94-96 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Goldinger, SM; Zimmer, L; Schulz, C; Ugurel, S; Hoeller, C; Kaehler, KC; Schadendorf, D; Hassel, JC; Becker, J; Hauschild, A; Dummer, R; Dermatology Cooperative Oncology Group (DeCOG) Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Eur J Cancer. 2014; 50(2):406-410
Web of Science PubMed FullText FullText_MUG

 

** Ugurel, S; Mentzel, T; Utikal, J; Helmbold, P; Mohr, P; Pföhler, C; Schiller, M; Hauschild, A; Hein, R; Kämpgen, E; Kellner, I; Leverkus, M; Becker, JC; Ströbel, P; Schadendorf, D Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
Clin Cancer Res. 2014; 20(2):499-510 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Übersichtsarbeiten

** Aigner, B; Ugurel, S; Kaddu, S; Becker, JC [Cutaneous sarcomas: update on selected fibrohistiocytic and myofibroblastic tumors].
Hautarzt. 2014; 65(7):614-622
Web of Science PubMed FullText FullText_MUG

 

Abstracts (Zeitschrift)

** Schrama, D; Groesser, L; Haffner, C; Ugurel, S; Pastrana, D; Buck, C; Cerroni, L; Theiler, A; Becker, JC Presence of human polyomavirus 6 in mutation-specific BRAF inhibitor induced epithelial proliferations
J DTSCH DERMATOL GES. 2014; 12: 42-42.-Deutscher Hautkrebskongress und ADO-Jahrestagung; SEP 11-13 2014; Frankfurt am Main, GERMANY. [Poster]
Web of Science

 

2013

Originalarbeiten (Zeitschrift)

** Aigner, B; Richtig, E; Becker, JC; Lingitz, H; Niederkorn, RMA; Ugurel, S; Partial Response of Metastatic Mucosal Melanoma After Palliative Chemotherapy With Trofosfamide: A Case Report.
J Clin Oncol. 2013; 31(2):e31-e32 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Degen, A; Weichenthal, M; Ugurel, S; Trefzer, U; Kilian, K; Garbe, C; Egberts, F; Poppe, LM; Hauschild, A; Gutzmer, R; Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial).
J DTSCH DERMATOL GES. 2013; 11(9): 846-854.
Web of Science FullText FullText_MUG

 

** O'Day, SJ; Eggermont, AMM; Chiarion-Sileni, V; Kefford, R; Grob, JJ; Mortier, L; Robert, C; Schachter, J; Testori, A; Mackiewicz, J; Friedlander, P; Garbe, C; Ugurel, S; Collichio, F; Guo, W; Lufkin, J; Bahcall, S; Vukovic, V; Hauschild, A; Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma.
J Clin Oncol. 2013; 31(9):1211-1218 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Ugurel, S; Kortmann, RD; Mohr, P; Mentzel, T; Garbe, C; Breuninger, H Brief S2k guidelines--Dermatofibrosarcoma protuberans.
J Dtsch Dermatol Ges. 2013; 11 Suppl 3(42): 17- 19
Web of Science PubMed FullText FullText_MUG

 

Kurzbericht/Letter

** Poppe, LM; Müller, PA; Poppe, H; Bröcker, EB; Ugurel, S; Weyandt, GH Chronic perianal ulceration as the initial symptom of Langerhans cell histiocytosis in adults.
Eur J Dermatol. 2013; 23(4):551-552 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Abstracts (Zeitschrift)

** Becker, J; Pflugfelder, A; Trefzer, U; Ugurel, S; Pfohler, C; Kellner, Y; Beissert, S; Kahler, K; Mohr, P; Zouboulis, C; Zimmer, L; Belloni, B; Berking, C; Schadendorf, D; Merkel Cell Carcinoma Register of the ADO - the first Evaluation.
J DTSCH DERMATOL GES. 2013; 11(9):909-910.-Deutscher Hautkrebskongress; September, 2013; Essen, D. [Oral Communication]
Web of Science

 

** Schrama, D; Ugurel, S; Schadendorf, D; Becker, JC; No association of STAT3 rs4796793 SNP with response to IFN alpha therapy in patients with metastatic melanoma.
EXP DERMATOL. 2013; 22(3):E22-E22.-40th Annual Meeting of the Association-of-Dermatological-Research; MAR 14-16, 2013; Dessau, GERMANY. [Poster]
Web of Science

 

** Ugurel, S; Mentzel, T; Utikal, J; Helmbold, P; Mohr, P; Pfohler, C; Schiller, M; Hauschild, A; Hein, R; Kampgen, E; Kellner, I; Leverkus, M; Becker, J; Strobel, P; Schadendorf, D. Neo-adjuvant Therapy of Dermatofibrosarcoma protuberans with Imatinib: A multicenter Phase II Study of the ADO.
J DTSCH DERMATOL GES. 2013; 11(9):909-909.-ADO-Tagung; September, 2013; Essen, D. [Oral Communication]
Web of Science

 

Kommentare

** Ugurel, S; Paschen, A; Becker, JC Dacarbazine in melanoma: from a chemotherapeutic drug to an immunomodulating agent.
J Invest Dermatol. 2013; 133(2):289-292 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2012

Originalarbeiten (Zeitschrift)

** Becker, JC; Andersen, MH; Hofmeister-Muller, V; Wobser, M; Frey, L; Sandig, C; Walter, S; Singh-Jasuja, H; Kampgen, E; Opitz, A; Zapatka, M; Brocker, EB; Straten, PT; Schrama, D; Ugurel, S; Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma.
Cancer Immunol Immunother. 2012; 61(11):2091-2103 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Gutzmer, R; Wollenberg, A; Ugurel, S; Homey, B; Ganser, A; Kapp, A Cutaneous side effects of new antitumor drugs: clinical features and management.
Dtsch Arztebl Int. 2012; 109(8):133-140 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Übersichtsarbeiten

** Schrama, D; Ugurel, S; Becker, JC Merkel cell carcinoma: recent insights and new treatment options.
Curr Opin Oncol. 2012; 24(2): 141-149.
Web of Science PubMed FullText FullText_MUG

 

Abstracts (Zeitschrift)

** Aigner, B; Richtig, E; Becker, J; Marterer, R; Niederkom, A; Lingitz, H; Ugurel, S; Partial Remission of metastatic Mucosal melanoma receiving palliative therapy with Trofosfamide.
J DTSCH DERMATOL GES. 2012; 10(9):695-695.-ADO; Hannover. [Poster]
Web of Science

 

** Livingstone, E; Eigentler, T; Windemuth-Kieselbach, C; Rompel, R; Trefzer, U; Nashan, D; Ugurel, S; Gesierich, A; Kahler, K; Schadendorf, D; Quality Assurance Project melanoma: Results of the Interim Survey 2 years after Initial diagnosis.
J DTSCH DERMATOL GES. . 2012; 10(9):678-678. [Poster]
Web of Science

 

2011

Originalarbeiten (Zeitschrift)

** Egberts, F; Gutzmer, R; Ugurel, S; Becker, JC; Trefzer, U; Degen, A; Schenck, F; Frey, L; Wilhelm, T; Hassel, JC; Schadendorf, D; Livingstone, E; Mauch, C; Garbe, C; Berking, C; Rass, K; Mohr, P; Kaehler, KC; Weichenthal, M; Hauschild, A Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial.
Ann Oncol. 2011; 22(7):1667-1674 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Schrama, D; Scherer, D; Schneider, M; Zapatka, M; Bröcker, EB; Schadendorf, D; Ugurel, S; Kumar, R; Becker, JC ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln Polymorphisms Are Independent Prognostic Factors for the Clinical Course of Melanoma.
J Invest Dermatol. 2011; 131(6):1280-1290 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Ugurel, S; Becker, JC Treatment of advanced metastatic melanoma
HAUTARZT. 2011; 62(6): 423-429.
Web of Science FullText FullText_MUG

 

Editorials

** Ugurel, S Chemotherapy in metastatic melanoma - still useful or out of date?
Onkologie. 2011; 34(4):159-160 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Abstracts (Zeitschrift)

** Degen, A; Weichenthal, M; Ugurel, S; Trefzer, U; Gauwerky, K; Garbe, C; Egberts, F; Frey, L; Hauschild, A; Gutzmer, R Cutaneous Side Effects of combination Therapy with Sorafenib and Peginterferon - an Evaluation of the SoraPeg Study of the ADO
J DTSCH DERMATOL GES. . 2011; 9(9):779-779.-21. Deutscher Hautkrebs-Kongress 2011 und ADO Jahrestagung; SEP 15-17, 2011; Weimar, GERMANY. [Poster]
Web of Science

 

** Heinemann, A; Sucker, A; Steinle, A; Eberle, J; Ugurel, S; Schadendorf, D; Paschen, A Connecting expression of the immunological cell stress indicator ULBP2 to the tumor suppressor activity of p53
EXP DERMATOL. . 2011; 20(2):P117--38th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF); FEB 17-19, 2011; Tuebingen, GERMANY. [Poster]
Web of Science

 

** Justich, A; Niederkorn, A; Tilz, H; Massone, C; Richtig, E; Becker, J; Ugurel, S Regression of a case of complete Paraplegia due to multiple Vertebral Body Metastases of a Melanoma being treated by BRAF-Inhibitor Vemurafenib
J DTSCH DERMATOL GES. 2011; 9(9):786-786.-21. Jahrestagung der ADO; Sept 15-17, 2011; Weimar, Deutschland. [Poster]
Web of Science

 

** Niederkorn, A; Tilz, HE; Justich, A; Richtig, E; Ugurel, S; Becker, J Response of an inoperative Relapse of a primary cutaneous large B-Cell-Lymphoma with endonasal Infiltration during Chemotherapy with pegylated liposomal Doxorubicine in Combination with Rituximab.
J DTSCH DERMATOL GES. 2011; 9(9):787-787.-21. Jahrestagung der ADO; Sept 15-17, 2011; Weimar, Deutschland. [Poster]
Web of Science

 

** Richtig, E; Ugurel, S; Niederkorn, A; Justich, A; Tilz, H; Becker, J Onset and rapid Progression of Vitiligo in a Patient with metastatic malignant Melanoma under Ipilimumag Therapy - possibly triggered by an increase in ACTH Process?
J DTSCH DERMATOL GES. 2011; 9(9):784-784.-21. Jahrestagung der ADO; Sept 15-17, 2011; Weimar, Deutschland. [Poster]
Web of Science

 

** Richtig, E; Ugurel, S; Niederkorn, A; Justich, A; Tilz, H; Becker, J Increase of Pancreatic Enzymes and of the Cortisol Levels in Patients with metastatic Melanoma under a Therapy with Ipilimumab
J DTSCH DERMATOL GES. 2011; 9(9):784-784.-21. Jahrestagung der ADO; Sept 15-17, 2011; Weimar, Deutschland. [Poster]
Web of Science

 

** Tilz, HE; Niederkorn, A; Justich, A; Prettenhofer, U; Massone, C; Richtig, E; Becker, J; Ugurel, S Successful Therapy of a Stewart Treves Angio Sarcoma by way of Radiation and Paclitaxel
J DTSCH DERMATOL GES. 2011; 9(9):789-789. [Poster]
Web of Science

 

2010

Originalarbeiten (Zeitschrift)

** Haagen, J; Hartmann, JT; Schmidt, M; Ugurel, S; Ulrich, J; Dörr, W Side effect of oncological treatment in skin and adnexae.
MMW Fortschr Med. 2010; 152(46):34-36
PubMed

 

Kurzbericht/Letter

** Houben, R; Schrama, D; Alb, M; Pfohler, C; Trefzer, U; Ugurel, S; Becker, JC Comparable expression and phosphorylation of the retinoblastoma protein in Merkel cell polyoma virus-positive and negative Merkel cell carcinoma.
Int J Cancer. 2010; 126(3):796-798 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Wobser, M; Göppner, D; Lang, SC; Beckmann, G; Flentje, M; Ugurel, S; Bröcker, EB; Becker, JC Durable complete remission of therapy-refractory, tumor-stage cutaneous T-cell lymphoma under radioimmunotherapy with electron beam irradiation and denileukin diftitox.
Arch Dermatol. 2010; 146(7):805-806 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Übersichtsarbeiten

** Becker, JC; Houben, R; Schrama, D; Voigt, H; Ugurel, S; Reisfeld, RA Mouse models for melanoma: a personal perspective.
Exp Dermatol. 2010; 19(2): 157-164. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Abstracts (Zeitschrift)

** Heinemann, A; Sucker, A; Moll, I; Steinle, A; Schadendorf, D; Becker, J; Ugurel, S; Paschen, A The Role of ULBP2 in Melanoma: Clinical Significance and Regulation.
J DTSCH DERMATOL GES. 2010; 8(9):749-749.-20. Deutscher Hautkrebskongress und ADO Jahrestagung ; Sep 23-25, 2010; Kiel, Germany . [Poster]
Web of Science

 

2009

Originalarbeiten (Zeitschrift)

** Findeisen, P; Zapatka, M; Peccerella, T; Matzk, H; Neumaier, M; Schadendorf, D; Ugurel, S Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
J Clin Oncol. 2009; 27(13):2199-2208 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Frey, L; Vetter-Kauczok, C; Gesierich, A; Bröcker, EB; Ugurel, S Cutaneous metastases as the first clinical sign of metastatic gastric carcinoma.
J Dtsch Dermatol Ges. 2009; 7(10):893-895 (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Gebhardt, C; Averbeck, M; Paasch, U; Ugurel, S; Kurzen, H; Stumpp, P; Simon, JC; Treudler, R A case of cutaneous Rosai-Dorfman disease refractory to imatinib therapy.
Arch Dermatol. 2009; 145(5):571-574 (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Kneitz, H; Bröcker, EB; Ugurel, S Slowly changing nodules on both lower limbs in a 54-year old patient.
J Dtsch Dermatol Ges. 2009; 7(1):63-65 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

** Paschen, A; Sucker, A; Hill, B; Moll, I; Zapatka, M; Nguyen, XD; Sim, GC; Gutmann, I; Hassel, J; Becker, JC; Steinle, A; Schadendorf, D; Ugurel, S Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
Clin Cancer Res. 2009; 15(16):5208-5215 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Wobser, M; Kurzinger, N; Ugurel, S; Brocker, EB; Becker, JC Therapy of metastasized Merkel cell carcinoma with liposomal doxorubicin in combination with radiotherapy.
J Dtsch Dermatol Ges. 2009; 7(6):521-525
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Kurzbericht/Letter

** Becker, JC; Houben, R; Ugurel, S; Trefzer, U; Pfohler, C; Schrama, D MC polyomavirus is frequently present in Merkel cell carcinoma of European patients.
J Invest Dermatol. 2009; 129(1):248-250 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Hofmann, UB; Wobser, M; Kneitz, H; Kleine, P; Becker, JC; Brocker, EB; Ugurel, S Major response to paclitaxel combined with irradiation as second-line therapy in metastatic angiosarcoma of the face and scalp.
Br J Dermatol. 2009; 160(2):456-458 (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Übersichtsarbeiten

** Ugurel, S; Utikal, J; Becker, JC Tumor biomarkers in melanoma.
Cancer Control. 2009; 16(3):219-224 [OPEN ACCESS]
Web of Science PubMed FullText

 

2008

Originalarbeiten (Zeitschrift)

** Hahn, S; Ugurel, S; Hanschmann, KM; Strobel, H; Tondera, C; Schadendorf, D; Löwer, J; Löwer, R Serological response to human endogenous retrovirus K in melanoma patients correlates with survival probability.
AIDS Res Hum Retroviruses. 2008; 24(5):717-723
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Hauschild, A; Dummer, R; Ugurel, S; Kaehler, KC; Egberts, F; Fink, W; Both-Skalsky, J; Laetsch, B; Schadendorf, D Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study.
Cancer. 2008; 113(6):1404-1411 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Hauschild, A; Trefzer, U; Garbe, C; Kaehler, KC; Ugurel, S; Kiecker, F; Eigentler, T; Krissel, H; Schott, A; Schadendorf, D Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.
Melanoma Res. 2008; 18(4):274-278
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Schrama, D; Keller, G; Houben, R; Ziegler, CG; Vetter-Kauczok, CS; Ugurel, S; Becker, JC BRAFV600E mutations in malignant melanoma are associated with increased expressions of BAALC.
J Carcinog. 2008; 7(1):1-1 [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG Google Scholar

 

** Spieth, K; Kaufmann, R; Dummer, R; Garbe, C; Becker, JC; Hauschild, A; Tilgen, W; Ugurel, S; Beyeler, M; Brocker, EB; Kaehler, KC; Pfohler, C; Gille, J; Leiter, U; Schadendorf, D Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG)
ANN ONCOL. 2008; 19(4): 801-806. [OPEN ACCESS]
Web of Science FullText FullText_MUG Google Scholar

 

** Ugurel, S In vitro drug sensitivity profiling in melanoma.
J Dtsch Dermatol Ges. 2008; 6(7):611-611
PubMed FullText FullText_MUG

 

** Ugurel, S; Kortmann, RD; Mohr, P; Mentzel, T; Garbe, C; Breuninger, H Short German guidelines: dermatofibrosarcoma protuberans.
J Dtsch Dermatol Ges. 2008; 6 Suppl 1(11):S17-S18
PubMed FullText FullText_MUG

 

** Ugurel, S; Schrama, D; Keller, G; Schadendorf, D; Brocker, EB; Houben, R; Zapatka, M; Fink, W; Kaufman, HL; Becker, JC Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy.
Cancer Immunol Immunother. 2008; 57(5):685-691
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Übersichtsarbeiten

** Becker, JC; Kauczok, CS; Ugurel, S; Eib, S; Brocker, EB; Houben, R Merkel cell carcinoma: molecular pathogenesis, clinical features and therapy.
J Dtsch Dermatol Ges. 2008; 6(9):709-719
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Becker, JC; Ugurel, S; Schrama, D Strategies to optimize the use of targeted agents for tumor therapy.
J Dtsch Dermatol Ges. 2008; 6(4):281-285
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Pföhler, C; Ugurel, S Cutaneous reactions to molecular targeted therapies.
Hautarzt. 2008; 59(10):814-820
Web of Science PubMed FullText FullText_MUG

 

** Ugurel, S Dermatofibrosarcoma protuberans.
Hautarzt. 2008; 59(11):933-939
Web of Science PubMed FullText FullText_MUG

 

** Ugurel, S; Enk, A Skin cancer: follow-up, rehabilitation, palliative and supportive care.
J Dtsch Dermatol Ges. 2008; 6(6):492-498
Web of Science PubMed FullText FullText_MUG

 

** Ulrich, J; Hartmann, JT; Dörr, W; Ugurel, S Skin toxicity of anti-cancer therapy.
J Dtsch Dermatol Ges. 2008; 6(11):959-977
PubMed FullText FullText_MUG

 

2007

Originalarbeiten (Zeitschrift)

** Figl, A; Thirumaran, RK; Ugurel, S; Gast, A; Hemminki, K; Kumar, R; Schadendorf, D Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants.
Arch Dermatol. 2007; 143(4):495-499 (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Matharoo-Ball, B; Ratcliffe, L; Lancashire, L; Ugurel, S; Miles, AK; Weston, DJ; Rees, R; Schadendorf, D; Ball, G; Creaser, CS Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/bioinformatic approach.
Proteomics Clin Appl. 2007; 1(6):605-620
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Ugurel, S Targeted therapy of dermatofibrosarcoma with imatinib.
J Dtsch Dermatol Ges. 2007; 5(3):261-261
PubMed FullText FullText_MUG

 

** Ugurel, S; Houben, R; Schrama, D; Voigt, H; Zapatka, M; Schadendorf, D; Brocker, EB; Becker, JC Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response.
Clin Cancer Res. 2007; 13(21):6344-6350 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Ugurel, S; Thirumaran, RK; Bloethner, S; Gast, A; Sucker, A; Mueller-Berghaus, J; Rittgen, W; Hemminki, K; Becker, JC; Kumar, R; Schadendorf, D B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact Prognosis
PLOS ONE. 2007; 2(2): [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG Google Scholar

 

** Utikal, J; Ugurel, S; Kurzen, H; Erben, P; Reiter, A; Hochhaus, A; Nebe, T; Hildenbrand, R; Haberkorn, U; Goerdt, S; Schadendorf, D Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses.
Arch Dermatol. 2007; 143(6):736-740 (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Übersichtsarbeiten

** Hauschild, A; Schadendorf, D; Garbe, C; Ugurel, S; Kähler, KC New promises in the adjuvant, and palliative treatment of melanoma.
Cancer Treat Res. 2007; 135(21):277-292
PubMed

 

** Utikal, J; Schadendorf, D; Ugurel, S Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies.
Arch Dermatol Res. 2007; 298(10):469-477 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG Google Scholar

 

Kommentare

** Becker, JC; Brocker, EB; Schadendorf, D; Ugurel, S Imatinib in melanoma: a selective treatment option based on KIT mutation status?
J Clin Oncol. 2007; 25(7):e9-e9 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2006

Originalarbeiten (Zeitschrift)

** Becker, JC; Ugurel, S; Bröcker, EB; Schrama, D; Houben, R New therapeutic approaches for solid tumors: histone deacetylase, methyltransferase and proteasome inhibitors.
J Dtsch Dermatol Ges. 2006; 4(2):108-113
PubMed FullText FullText_MUG Google Scholar

 

** Bloethner, S; Hemminki, K; Thirumaran, RK; Chen, B; Mueller-Berghaus, J; Ugurel, S; Schadendorf, D; Kumar, R Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes.
Melanoma Res. 2006; 16(4):297-307
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Fensterle, J; Trefzer, U; Berger, T; Andersen, MH; Ugurel, S; Becker, JC HLA-B8 association with late-stage melanoma - an immunological lesson?
BMC MED. 2006; 4: [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Hoek, KS; Schlegel, NC; Brafford, P; Sucker, A; Ugurel, S; Kumar, R; Weber, BL; Nathanson, KL; Phillips, DJ; Herlyn, M; Schadendorf, D; Dummer, R Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.
Pigment Cell Res. 2006; 19(4):290-302
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Houben, R; Michel, B; Vetter-Kauczok, CS; Pfohler, C; Laetsch, B; Wolter, MD; Leonard, JH; Trefzer, U; Ugurel, S; Schrama, D; Becker, JC Absence of classical MAP kinase pathway signalling in Merkel cell carcinoma.
J Invest Dermatol. 2006; 126(5):1135-1142 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Müller-Berghaus, J; Ehlert, K; Ugurel, S; Umansky, V; Bucur, M; Schirrmacher, V; Beckhove, P; Schadendorf, D Melanoma-reactive T cells in the bone marrow of melanoma patients: association with disease stage and disease duration.
Cancer Res. 2006; 66(12):5997-6001 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Schadendorf, D; Hauschild, A; Ugurel, S; Thoelke, A; Egberts, F; Kreissig, M; Linse, R; Trefzer, U; Vogt, T; Tilgen, W; Mohr, P; Garbe, C Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Ann Oncol. 2006; 17(10):1592-1597 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Schadendorf, D; Ugurel, S; Schuler-Thurner, B; Nestle, FO; Enk, A; Brocker, EB; Grabbe, S; Rittgen, W; Edler, L; Sucker, A; Zimpfer-Rechner, C; Berger, T; Kamarashev, J; Burg, G; Jonuleit, H; Tuttenberg, A; Becker, JC; Keikavoussi, P; Kampgen, E; Schuler, G Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.
Ann Oncol. 2006; 17(4):563-570 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Schledzewski, K; Falkowski, M; Moldenhauer, G; Metharom, P; Kzhyshkowska, J; Ganss, R; Demory, A; Falkowska-Hansen, B; Kurzen, H; Ugurel, S; Geginat, G; Arnold, B; Goerdt, S Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis.
J Pathol. 2006; 209(1):67-77
Web of Science PubMed FullText FullText_MUG

 

** Thoelke, A; Schmid, HP; Figl, R; Schadendorf, D; Ugurel, S Jo-1 positive paraneoplastic systemic sclerosis in a patient with metastatic melanoma.
Eur J Dermatol. 2006; 16(4):428-430 (- Case Report) [OPEN ACCESS]
Web of Science PubMed Google Scholar

 

** Ugurel, S; Schadendorf, D; Pföhler, C; Neuber, K; Thoelke, A; Ulrich, J; Hauschild, A; Spieth, K; Kaatz, M; Rittgen, W; Delorme, S; Tilgen, W; Reinhold, U; Dermatologic Cooperative Oncology Group In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
Clin Cancer Res. 2006; 12(18):5454-5463 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Kurzbericht/Letter

** Utikal, J; Thoelke, A; Becker, JC; Figl, R; Goerdt, S; Schadendorf, D; Ugurel, S Local cutaneous argyria mimicking melanoma metastases in a patient with disseminated melanoma.
J Am Acad Dermatol. 2006; 55(5 Suppl):S92-S94 (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Utikal, J; Zimpfer, A; Thoelke, A; Figl, R; Hildenbrand, R; Kettelhack, C; Goerdt, S; Schadendorf, D; Ugurel, S Complete remission of multiple satellite and in-transit melanoma metastases after sequential treatment with isolated limb perfusion and topical imiquimod.
Br J Dermatol. 2006; 155(2):488-491 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Kommentare

** Thirumaran, RK; Thoelke, A; Ugurel, S; Hemminki, K; Schadendorf, D; Kumar, R Re: Association between endothelin receptor B nonsynonymous variants and melanoma risk.
J Natl Cancer Inst. 2006; 98(17):1252-1253 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Ugurel, S; Houben, R; Becker, JC Molecular mechanisms in melanoma.
N Engl J Med. 2006; 355(13):1395-1396 [OPEN ACCESS]
Web of Science PubMed Google Scholar

 

2005

Originalarbeiten (Zeitschrift)

** Bauer, U; Ugurel, S; Utikal, J; Schadendorf, D; Goerdt, S 90-year-old male with a hyperkeratotic lichenoid skin eruption.
J Dtsch Dermatol Ges. 2005; 3(2):137-139 (- Case Report)
PubMed

 

** Bloethner, S; Chen, B; Hemminki, K; Müller-Berghaus, J; Ugurel, S; Schadendorf, D; Kumar, R Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.
Carcinogenesis. 2005; 26(7):1224-1232 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Mian, S; Ugurel, S; Parkinson, E; Schlenzka, I; Dryden, I; Lancashire, L; Ball, G; Creaser, C; Rees, R; Schadendorf, D Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients.
J Clin Oncol. 2005; 23(22):5088-5093 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Ugurel, S Serum markers for melanoma.
Hautarzt. 2005; 56(2):173-184
Web of Science PubMed FullText FullText_MUG

 

** Ugurel, S; Bell, N; Sucker, A; Zimpfer, A; Rittgen, W; Schadendorf, D Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma.
Int J Cancer. 2005; 117(5):825-830
Web of Science PubMed FullText FullText_MUG

 

** Ugurel, S; Hildenbrand, R; Zimpfer, A; La Rosee, P; Paschka, P; Sucker, A; Keikavoussi, P; Becker, JC; Rittgen, W; Hochhaus, A; Schadendorf, D Lack of clinical efficacy of imatinib in metastatic melanoma.
Br J Cancer. 2005; 92(8):1398-1405 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG Google Scholar

 

2004

Originalarbeiten (Zeitschrift)

** Andersen, MH; Fensterle, J; Ugurel, S; Reker, S; Houben, R; Guldberg, P; Berger, TG; Schadendorf, D; Trefzer, U; Brocker, EB; Straten, PT; Rapp, UR; Becker, JC Immunogenicity of constitutively active (V599E)BRaf
CANCER RES. 2004; 64(15): 5456-5460. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Fink, W; Zimpfer-Rechner, C; Thoelke, A; Figl, R; Kaatz, M; Ugurel, S; Schadendorf, D Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma.
Onkologie. 2004; 27(6):540-544
Web of Science PubMed FullText FullText_MUG

 

** Pföhler, C; Steinhäuser, S; Wagner, A; Ugurel, S; Tilgen, W Complete remission of cutaneous satellite and in-transit metastases. After intralesional therapy with interleukin-2 in 2 patients with malignant melanoma.
Hautarzt. 2004; 55(2):171-175 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

** Ugurel, S; Uhlig, D; Pföhler, C; Tilgen, W; Schadendorf, D; Reinhold, U Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients.
Cancer Immunol Immunother. 2004; 53(6):551-559
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Kommentare

** Ugurel, S; Lindemann, M; Schadendorf, D; Grosse-Wilde, H Altered surface expression patterns of circulating monocytes in cancer patients: impaired capacity of T-cell stimulation?
Cancer Immunol Immunother. 2004; 53(11):1051-1051
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2003

Originalarbeiten (Zeitschrift)

** Fink, W; Zimpfer, A; Ugurel, S Mucosal metastases in malignant melanoma.
Onkologie. 2003; 26(3):249-251 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

** Pföhler, C; Cree, IA; Ugurel, S; Kuwert, C; Haass, N; Neuber, K; Hengge, U; Corrie, PG; Zutt, M; Tilgen, W; Reinhold, U Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study.
Anticancer Drugs. 2003; 14(5):337-340
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Pföhler, C; Haus, A; Palmowski, A; Ugurel, S; Ruprecht, KW; Thirkill, CE; Tilgen, W; Reinhold, U Melanoma-associated retinopathy: high frequency of subclinical findings in patients with melanoma.
Br J Dermatol. 2003; 149(1):74-78
Web of Science PubMed FullText FullText_MUG

 

** Ugurel, S; Hildenbrand, R; Dippel, E; Hochhaus, A; Schadendorf, D Dose-dependent severe cutaneous reactions to imatinib.
Br J Cancer. 2003; 88(8):1157-1159 (- Case Report) [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Ugurel, S; Lahaye, T; Hildenbrand, R; Glorer, E; Reiter, A; Hochhaus, A; Schadendorf, D; Goerdt, S Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib.
Br J Dermatol. 2003; 149(3):678-679 (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Ugurel, S; Tilgen, W; Reinhold, U Chemosensitivity testing in malignant melanoma.
Recent Results Cancer Res. 2003; 161(8):81-92
PubMed

 

Übersichtsarbeiten

** Ugurel, S; Schadendorf, D Systemic treatment in advanced melanoma: innovative perspectives.
Onkologie. 2003; 26(3):234-238
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2002

Originalarbeiten (Zeitschrift)

** Rappl, G; Abken, H; Muche, JM; Sterry, W; Tilgen, W; André, S; Kaltner, H; Ugurel, S; Gabius, HJ; Reinhold, U CD4+CD7- leukemic T cells from patients with Sézary syndrome are protected from galectin-1-triggered T cell death.
Leukemia. 2002; 16(5):840-845 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Rebmann, V; Ugurel, S; Tilgen, W; Reinhold, U; Grosse-Wilde, H Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients.
Int J Cancer. 2002; 100(5):580-585
Web of Science PubMed FullText FullText_MUG

 

Kurzbericht/Letter

** Ugurel, S; Wagner, A; Pföhler, C; Tilgen, W; Reinhold, U Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread.
Br J Dermatol. 2002; 147(3):621-624 (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Übersichtsarbeiten

** Ugurel, S; Reinhold, U; Tilgen, W HLA-G in melanoma: A new strategy to escape from immunosurveillance?
Onkologie. 2002; 25(2):129-134
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2001

Originalarbeiten (Zeitschrift)

** Gross, T; Wagner, A; Ugurel, S; Tilgen, W; Reinhold, U Identification of TIA-1+ and granzyme B+ cytotoxic T cells in lichen sclerosus et atrophicus.
Dermatology. 2001; 202(3):198-202
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Hauschild, A; Garbe, C; Stolz, W; Ellwanger, U; Seiter, S; Dummer, R; Ugurel, S; Sebastian, G; Nashan, D; Linse, R; Achtelik, W; Mohr, P; Kaufmann, R; Fey, M; Ulrich, J; Tilgen, W Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Br J Cancer. 2001; 84(8):1036-1042 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Rappl, G; Abken, H; Hasselmann, DO; Tilgen, W; Ugurel, S; Reinhold, U The CD7(-) subset of CD4(+) memory T cells is prone to accelerated apoptosis that is prevented by interleukin-15 (IL-15).
Cell Death Differ. 2001; 8(4):395-402 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Rappl, G; Hasselmann, DO; Rössler, M; Ugurel, S; Tilgen, W; Reinhold, U Detection of tumor-associated circulating mRNA in patients with disseminated malignant melanoma.
Ann N Y Acad Sci. 2001; 945(5):189-191
Web of Science PubMed

 

** Rappl, G; Kapsokefalou, A; Heuser, C; Rössler, M; Ugurel, S; Tilgen, W; Reinhold, U; Abken, H Dermal fibroblasts sustain proliferation of activated T cells via membrane-bound interleukin-15 upon long-term stimulation with tumor necrosis factor-alpha.
J Invest Dermatol. 2001; 116(1):102-109 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Rappl, G; Muche, JM; Abken, H; Sterry, W; Tilgen, W; Ugurel, S; Reinhold, U CD4(+)CD7(-) T cells compose the dominant T-cell clone in the peripheral blood of patients with Sézary syndrome.
J Am Acad Dermatol. 2001; 44(3):456-461
Web of Science PubMed FullText FullText_MUG

 

** Reinhold, U; Berkin, C; Bosserhoff, AK; Deutschmann, A; Garbe, C; Gläser, R; Hein, R; Krähn, G; Peter, RU; Rappl, G; Schittek, B; Seiter, S; Ugurel, S; Volkenandt, M; Tilgen, W Interlaboratory evaluation of a new reverse transcriptase polymerase chain reaction-based enzyme-linked immunosorbent assay for the detection of circulating melanoma cells: a multicenter study of the Dermatologic Cooperative Oncology Group.
J Clin Oncol. 2001; 19(6):1723-1727 [OPEN ACCESS]
Web of Science PubMed FullText Google Scholar

 

** Seiter, S; Rappl, G; Tilgen, W; Ugurel, S; Reinhold, U Facts and pitfalls in the detection of tyrosinase mRNA in the blood of melanoma patients by RT-PCR.
Recent Results Cancer Res. 2001; 158(1):105-112
PubMed Google Scholar

 

** Seiter, S; Ugurel, S; Tilgen, W; Reinhold, U High-dose pulse corticosteroid therapy in the treatment of severe alopecia areata.
Dermatology. 2001; 202(3):230-234
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Ugurel, S; Rappl, G; Tilgen, W; Reinhold, U Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients.
Clin Cancer Res. 2001; 7(5):1282-1286 [OPEN ACCESS]
Web of Science PubMed FullText Google Scholar

 

** Ugurel, S; Rappl, G; Tilgen, W; Reinhold, U Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival.
J Clin Oncol. 2001; 19(2):577-583 [OPEN ACCESS]
Web of Science PubMed FullText Google Scholar

 

** Ugurel, S; Rebmann, V; Ferrone, S; Tilgen, W; Grosse-Wilde, H; Reinhold, U Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy.
Cancer. 2001; 92(2):369-376
Web of Science PubMed FullText FullText_MUG

 

2000

Originalarbeiten (Zeitschrift)

** Hasselmann, DO; Rappl, G; Rössler, M; Ugurel, S; Tilgen, W; Reinhold, U Detection of tumor-associated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma.
Oncol Rep. 2000; 8(1):115-118
Web of Science PubMed

 

** Pföhler, C; Ugurel, S; Seiter, S; Wagner, A; Tilgen, W; Reinhold, U Interferon-alpha-associated development of bullous lesions in mycosis fungoides.
Dermatology. 2000; 200(1):51-53 (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Reinhold, U; Ugurel, S; Tilgen, W; Kadiata, MM; Olivares, E; Nadi, AB; Malaisse, WJ Antitumoral action of 2-deoxy-D-glucose tetraacetate in human melanoma cells.
Oncol Rep. 2000; 7(5):1093-1097
Web of Science PubMed Google Scholar

 

** Seiter, S; Ugurel, S; Tilgen, W; Reinhold, U Use of high-dose methylprednisolone pulse therapy in patients with progressive and stable vitiligo.
Int J Dermatol. 2000; 39(8):624-627
Web of Science PubMed FullText FullText_MUG

 

Kurzbericht/Letter

** Ugurel, S; Pföhler, C; Tilgen, W; Reinhold, U S100-beta serum protein--a new marker in the diagnosis and monitoring of Langerhans cell histiocytosis?
Br J Dermatol. 2000; 143(1):201-202 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

1999

Originalarbeiten (Zeitschrift)

** Reinhold, U; Seiter, S; Ugurel, S; Tilgen, W Treatment of progressive pigmented purpura with oral bioflavonoids and ascorbic acid: an open pilot study in 3 patients.
J Am Acad Dermatol. 1999; 41(2 Pt 1):207-208
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Seiter, S; Ugurel, S; Pföhler, C; Tilgen, W; Reinhold, U Successful treatment of progressive vitiligo with high-dose intravenous methylprednisolone 'pulse' therapy.
Dermatology. 1999; 199(3):261-262 (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Seiter, S; Ugurel, S; Tilgen, W; Reinhold, U Multiple granular cell tumors and growth hormone deficiency in a child.
Pediatr Dermatol. 1999; 16(4):308-310 (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Ugurel, S; Seiter, S; Rappl, G; Stark, A; Tilgen, W; Reinhold, U Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon-gamma.
Int J Cancer. 1999; 82(5):727-736
Web of Science PubMed FullText FullText_MUG

 

Kurzbericht/Letter

** Seiter, S; Gantenbein, C; Ugurel, S; Ruprecht, KW; Tilgen, W; Reinhold, U An oculocutaneous presentation of essential progressive telangiectasia.
Br J Dermatol. 1999; 140(5):969-971 (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar

 

© Meduni Graz Impressum